# Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis

> **NCT03828344** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Baylx Inc.** · enrollment: 16 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** hUC-MSC suspension
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03828344
- **Lead sponsor:** Baylx Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-02-20
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828344, "Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03828344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*